In early-stage lung cancer patients, achieving an MPR was highly associated with an increased tumor-mutational burden (TMB), similar to responses to PD-1 blockade in advanced NSCLC patients. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.